Virogen Biotechnology

Virogen Biotechnology is a clinical-stage biotech company dedicated to developing innovative immunotherapies targeting unmet needs in oncology and autoimmune diseases. With operations in both the U.S. and Asia, Virogen leverages global expertise to advance its therapeutic programs. Moffitt Cancer Center The company's lead candidate, VG712, is an immunotoxin-based therapy originally developed at the National Institutes of Health (NIH) by Dr. David Neville, a pioneer in immunotoxin research. VG712 is designed to clear and reboot T-cell function, addressing immune dysfunctions associated with various diseases, including malignant tumors and autoimmune disorders . Virogen's pipeline focuses on antibody-toxin conjugates targeting CD3, a critical component of T-cell activation. This approach aims to modulate the immune system effectively, offering potential treatments for conditions such as cutaneous T-cell lymphoma and other immune-related diseases . In collaboration with institutions like the Moffitt Cancer Center, Virogen is working to accelerate oncology and immunotherapy innovations, furthering its mission to address significant gaps in current treatment options . For more detailed information, please visit their official website: www.virogenbio.com.